Literature DB >> 25819167

Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis.

A J Brink1, G A Richards2, E E G Lautenbach3, N Rapeport4, V Schillack5, L van Niekerk6, J Lipman7, J A Roberts8.   

Abstract

The impact of decreased serum albumin concentrations on free antibiotic concentrations in non-critically ill patients is poorly described. This study aimed to describe the pharmacokinetics of a high-dose regimen of teicoplanin, a highly protein-bound antibiotic, in non-critically ill patients with hypoalbuminaemia. Ten patients with chronic bone sepsis and decreased serum albumin concentrations (<35 g/L) receiving teicoplanin 12 mg/kg 12-hourly intravenously for 48 h followed by 12 mg/kg once daily were enrolled. Surgical debridement was performed on Day 3. Samples of venous blood were collected pre-infusion and post-infusion during the first 4 days of therapy. Total and free teicoplanin concentrations were assayed using validated chromatographic methods. The median serum albumin concentration for the cohort was 18 (IQR 15-24) g/L. After 48 h, the median (IQR) free trough (fC(min)) and total trough (tC(min)) concentrations were 2.90 (2.67-3.47) mg/L and 15.54 (10.28-19.12) mg/L, respectively, although trough concentrations declined thereafter. Clearance of the free concentrations was significantly high relative to the total fraction at 38.6 (IQR 29.9-47.8) L/h and 7.0 (IQR 6.8-9.8) L/h, respectively (P<0.001). Multiple linear regression analysis demonstrated that whereas total teicoplanin concentration did not impact on free concentrations (P=0.174), albumin concentration did (P<0.001). This study confirms the significant impact of hypoalbuminaemia on free concentrations of teicoplanin in non-critically ill patients, similar to that in critically ill patients. Furthermore, the poor correlation with total teicoplanin concentration suggests that therapeutic drug monitoring of free concentrations should be used in these patients.
Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Free; Hypoalbuminaemia; Population pharmacokinetics; Protein binding; TDM; Teicoplanin

Mesh:

Substances:

Year:  2015        PMID: 25819167     DOI: 10.1016/j.ijantimicag.2015.01.015

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.

Authors:  Catherine J Byrne; Jason A Roberts; Brett McWhinney; Jerome P Fennell; Philomena O'Byrne; Evelyn Deasy; Sean Egan; Ronan Desmond; Helen Enright; Sheila A Ryder; Deirdre M D'Arcy; Johnny McHugh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  Prognostic value of prealbumin, N-terminal pro-B-type natriuretic peptide, heart type fatty acid binding protein, and cardiac troponin I in elderly patients for heart failure and poor outcomes.

Authors:  Shengzhuo Wang; Ketong Liu; Shoukun Guan; Ge Cui
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

3.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

Review 4.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440

5.  Construction and Interpretation of Prediction Model of Teicoplanin Trough Concentration via Machine Learning.

Authors:  Pan Ma; Ruixiang Liu; Wenrui Gu; Qing Dai; Yu Gan; Jing Cen; Shenglan Shang; Fang Liu; Yongchuan Chen
Journal:  Front Med (Lausanne)       Date:  2022-03-08

6.  Dose Optimization of Teicoplanin for Critically Ill Patients With Renal Dysfunction and Continuous Renal Replacement Therapy: Experience From a Prospective Interventional Study.

Authors:  Lu Shi; Zhiwei Zhuang; Lufen Duan; Chenqi Zhu; Hongzhi Xue; Xiao Wang; Xiaowen Xu; Yunlong Yuan; Ling Shi; Jiahui Li; Jiantong Sun; Xin Liu; Qin Zhou; Jian Lu; Lian Tang
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.